OXILAN-350
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXILAN-350 is an injectable diagnostic or therapeutic agent manufactured by Guerbet, approved in 1995. The specific indication and mechanism of action are not publicly disclosed in available data, limiting characterization of its clinical role.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, signaling potential downsizing or transition of commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE status indicate limited hiring and career expansion on OXILAN-350. Professionals on this team should anticipate product management consolidation and transition planning within 2–5 years.
Brand ManagerMarket Access Manager
Worked on OXILAN-350 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.